A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker
- Aguiar, Pedro N., Jr.
- Santoro, Ilka Lopes
- Tadokoro, Hakaru
- Lopes, Gilberto de Lima
- Filardi, Bruno Andraus
- Oliveira, Pedro
- Castelo-Branco, Pedro
- Mountzios, Giannis
- de Mello, Ramon Andrade
DOIAbstract
Background: Recent studies with nivolumab (a monoclonal antibody against programmed cell death 1 [PD-1] receptor) have shown promise non-small-cell lung cancer (NSCLC) treatment. Methods: To review available clinical trials data in order to assess nivolumab efficacy and the role of tumoral PDL-1 expression as a biomarker. Results: Nine eligible studies included 2102 patients. In the second line setting, nivolumab achieved a 1-year survival rate of 41%; and in the first line, a 1-year survival rate of 76%. For those with PD-L1 expression <1%, nivolumab showed a trend for improved survival compared with docetaxel. Conclusions: The available data reinforce nivolumab activity against NSCLC in first-line or subsequent lines. Although PD-L1 expre...
Add to ORKG